Stephanie Shiau1, Renate Strehlau, Karl-Günter Technau, Faeezah Patel, Stephen M Arpadi, Ashraf Coovadia, Elaine J Abrams, Louise Kuhn. 1. aGertrude H. Sergievsky Center, College of Physicians and Surgeons, Columbia University, New York City, New York, USA bDepartment of Epidemiology, Mailman School of Public Health, Columbia University, New York City, New York, USA cDepartment of Paediatrics and Child Health, Faculty of Health Sciences, Empilweni Service and Research Unit, Rahima Moosa Mother and Child Hospital, University of the Witwatersrand, Johannesburg, South Africa dICAP, Mailman School of Public Health eDepartment of Pediatrics, College of Physicians and Surgeons, Columbia University, New York City, New York, USA.
Abstract
OBJECTIVE: The report of the 'Mississippi baby' who was initiated on antiretroviral therapy (ART) within 30 h of birth and maintained viral suppression off ART for 27 months has increased interest in the timing of ART initiation early in life. We examined associations between age at ART initiation and virologic outcomes in five cohorts of HIV-infected infants and young children who initiated ART before 2 years of age in Johannesburg, South Africa. METHODS: We compared those who initiated ART early (<6 months of age) and those who started ART late (6-24 months of age). Two primary outcomes were examined: initial response to ART in three cohorts and later sustained virologic control after achieving suppression on ART in two cohorts. RESULTS: We did not observe consistent differences in initial viral suppression rates by age at ART initiation. Overall, initial viral suppression rates were low. Only 31, 40.1, and 26.5% of early-treated infants (<6 months of age) in the three cohorts, respectively, were suppressed less than 50 copies/ml of HIV RNA 6 months after starting ART. We did observe better sustained virologic control after achieving suppression on ART among infants starting ART early compared with late. Children who started ART early were less likely to experience viral rebound (>50 copies/ml or >1000 copies/ml) than children who started late in both cohorts. CONCLUSION: These findings provide additional support for early initiation of ART in HIV-infected infants.
OBJECTIVE: The report of the 'Mississippi baby' who was initiated on antiretroviral therapy (ART) within 30 h of birth and maintained viral suppression off ART for 27 months has increased interest in the timing of ART initiation early in life. We examined associations between age at ART initiation and virologic outcomes in five cohorts of HIV-infectedinfants and young children who initiated ART before 2 years of age in Johannesburg, South Africa. METHODS: We compared those who initiated ART early (<6 months of age) and those who started ART late (6-24 months of age). Two primary outcomes were examined: initial response to ART in three cohorts and later sustained virologic control after achieving suppression on ART in two cohorts. RESULTS: We did not observe consistent differences in initial viral suppression rates by age at ART initiation. Overall, initial viral suppression rates were low. Only 31, 40.1, and 26.5% of early-treated infants (<6 months of age) in the three cohorts, respectively, were suppressed less than 50 copies/ml of HIV RNA 6 months after starting ART. We did observe better sustained virologic control after achieving suppression on ART among infants starting ART early compared with late. Children who started ART early were less likely to experience viral rebound (>50 copies/ml or >1000 copies/ml) than children who started late in both cohorts. CONCLUSION: These findings provide additional support for early initiation of ART in HIV-infectedinfants.
Authors: E J H Schatorjé; E F A Gemen; G J A Driessen; J Leuvenink; R W N M van Hout; E de Vries Journal: Scand J Immunol Date: 2012-04 Impact factor: 3.487
Authors: Barbara Laughton; Morna Cornell; Debbie Grove; Martin Kidd; Priscilla E Springer; Els Dobbels; Anita J van Rensburg; Avy Violari; Abdel G Babiker; Shabir A Madhi; Patrick Jean-Philippe; Diana M Gibb; Mark F Cotton Journal: AIDS Date: 2012-08-24 Impact factor: 4.177
Authors: Vivek Jain; Wendy Hartogensis; Peter Bacchetti; Peter W Hunt; Hiroyu Hatano; Elizabeth Sinclair; Lorrie Epling; Tzong-Hae Lee; Michael P Busch; Joseph M McCune; Christopher D Pilcher; Frederick M Hecht; Steven G Deeks Journal: J Infect Dis Date: 2013-07-12 Impact factor: 5.226
Authors: K McIntosh; A Shevitz; D Zaknun; J Kornegay; P Chatis; N Karthas; S K Burchett Journal: Pediatr Infect Dis J Date: 1996-12 Impact factor: 2.129
Authors: Dimitri Van der Linden; Marc Hainaut; Tessa Goetghebuer; Edwige Haelterman; Véronique Schmitz; Philip Maes; Alexandra Peltier; Jack Levy Journal: Pediatr Infect Dis J Date: 2007-04 Impact factor: 2.129
Authors: Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre Journal: N Engl J Med Date: 2008-11-20 Impact factor: 91.245
Authors: Stephanie Shiau; Stephen M Arpadi; Megan Burke; Afaaf Liberty; Cara Thurman; Faeezah Patel; Renate Strehlau; Elaine J Abrams; Ashraf Coovadia; Avy Violari; Louise Kuhn Journal: AIDS Care Date: 2019-07-09
Authors: Chloe A Teasdale; Nonzwakazi Sogaula; Katharine A Yuengling; Chunhui Wang; Anthony Mutiti; Stephen Arpadi; Mahlubandile Nxele; Lungile Pepeta; Mary Mogashoa; Emilia D Rivadeneira; Elaine J Abrams Journal: J Int AIDS Soc Date: 2018-08 Impact factor: 5.396
Authors: Babasola Okusanya; Linda J Kimaru; Namoonga Mantina; Lynn B Gerald; Sydney Pettygrove; Douglas Taren; John Ehiri Journal: PLoS One Date: 2022-02-25 Impact factor: 3.240